117 results on '"Sardeli, Chrysanthi"'
Search Results
2. Salicylate- and Noise-induced Tinnitus. Different Mechanisms Producing the same Result? An Experimental Model
- Author
-
Pavlidis, Pavlos, Papadopoulou, Kyriaki, Tseriotis, Vasilis Spyridon, Karachrysafi, Sophia, Sardeli, Chrysanthi, Gouveris, Haralampos, Papamitsou, Theodora, Sioga, Antonia, and Kouvelas, Dimitrios
- Published
- 2023
- Full Text
- View/download PDF
3. Epidemiology of antenatal depression among women with high-risk pregnancies due to obstetric complications: a scoping review
- Author
-
Tsakiridis, Ioannis, Bousi, Vasiliki, Dagklis, Themistoklis, Sardeli, Chrysanthi, Nikolopoulou, Vasiliki, and Papazisis, Georgios
- Published
- 2019
- Full Text
- View/download PDF
4. Sentinel Lymph Node Staging in Early-Stage Cervical Cancer: A Comprehensive Review.
- Author
-
Margioula-Siarkou, Chrysoula, Almperis, Aristarchos, Gullo, Giuseppe, Almperi, Emmanouela-Aliki, Margioula-Siarkou, Georgia, Nixarlidou, Eleni, Mponiou, Konstantina, Papakotoulas, Pavlos, Sardeli, Chrysanthi, Guyon, Frederic, Dinas, Konstantinos, and Petousis, Stamatios
- Subjects
SENTINEL lymph nodes ,SENTINEL lymph node biopsy ,CERVICAL cancer ,LITERATURE reviews ,LYMPH nodes - Abstract
Cervical cancer (CC) continues to be a significant global public health concern, even with preventive measures in place. In women with early-stage CC, the status of lymph nodes is of paramount importance, not only for the final prognosis but also for determining the best therapeutic strategy. According to main international guidelines, pelvic full lymphadenectomy (PLND) is recommended for lymph node staging. However, in these early stages of CC, sentinel lymph node biopsy (SLNB) has emerged as a precise technique for evaluating lymph node involvement, improving its morbidity profile. We performed a literature review through PubMed articles about progress on the application of SLNB in women with early-stage CC focusing on the comparison with PET/CT and PLND in terms of oncological outcomes and diagnostic accuracy. While the superiority of SLNB is clear compared to radiologic modalities, it demonstrates no clear oncologic inferiority over PLND, given the higher detection rate of positive lymph nodes and predominance of no lymph node recurrences. However, due to a lack of prospective evidence, particularly concerning long-term oncological safety, SLNB is not the current gold standard. With careful patient selection and adherence to straightforward protocols, a low false-negative rate can be ensured. The aim of the ongoing prospective trials is to address these issues. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Producing the appropriate model and drug for intratumoural ablation
- Author
-
Kosmidis, Christoforos, Sardeli, Chrysanthi, Zarogoulidis, Paul, Hohenforst-Schmidt, Wolfgang, Vagionas, Anastasios, Ioannis-Katsios, Nikolaos, and Sapalidis, Konstantinos
- Published
- 2020
- Full Text
- View/download PDF
6. Pharmacologic Stewardship in a Rural Community Pharmacy.
- Author
-
Sardeli, Chrysanthi, Athanasiadis, Theodoros, Stamoula, Eleni, and Kouvelas, Dimitrios
- Subjects
ANTIMICROBIAL stewardship ,CONFIDENCE intervals ,DRUGSTORES ,MEDICATION errors ,INTERVIEWING ,SELF medication ,CATASTROPHIC illness ,DRUG interactions ,QUESTIONNAIRES ,CHI-squared test ,DRUG side effects ,DATA analysis software ,ADVERSE health care events ,RURAL health clinics - Abstract
Background: Pharmacotherapy is an essential part of patient care. In order to achieve optimal health outcomes, safe and effective prescribing and administering of medications is crucial, especially since the process of pharmacotherapy can cause serious problems, mainly adverse events and/or interactions, that often pass undetected. Objective(s): To investigate the feasibility of using community pharmacies as checkpoints to detect errors and failures in prescribing, as well as patients' compliance with pharmacotherapy. To this end, analysis and recording of the prescribing process was carried out and error-prone points were identified. Methods: Patients and caregivers filling prescriptions during the first 4 weeks of November 2017 and February 2018 answered questions in order to evaluate their attendance of regular checkups and their compliance with prescribing instructions. All prescriptions filled at the pharmacy were examined for detection of prescription errors and drug–drug interactions. Statistical analyses, including calculations of the correlation coefficient phi (φ), chi-square, and confidence intervals, were carried out. Detected errors and failures were evaluated by application of the Health Failure Mode Effect Analysis (HFMEA) quality tool. Results: A significant number of patients (16.7%) failed to regularly attend checkups regarding known health problems (95% CI: 10.6–22.7%), a corresponding percentage (16%, 95% CI: 10.1–21.9%) did not comply with prescribed pharmacotherapy, and a significant proportion of patients self-medicated regularly (32%, 95% CI: 24.5–39.5%). A total of 8.6% of prescriptions included medication combinations with a potential for severe drug–drug interactions (95% CI: 7.1–10.2%) while 58.7% of the prescriptions included combinations that could lead to moderate ones (95% CI: 56.1–61.4). The HFMEA indicated that all problems recorded required immediate interventions, except for prescribing errors. Conclusions: Community pharmacies can be potential checkpoints for the detection and evaluation of prescribing errors and pharmacotherapy failures. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Immunotherapy for the elderly. Maybe the best option for lung cancer?
- Author
-
Zarogoulidis, Paul, Matthaios, Dimitris, Oikonomou, Panagoula, Nikolaou, Christina, Charalampidis, Charalampos, and Sardeli, Chrysanthi
- Published
- 2023
- Full Text
- View/download PDF
8. Sotorasib after immune checkpoint inhibitor administration induces hepatotoxicity. True, false or just another adverse effect of NSCLC treatment
- Author
-
Zarogoulidis, Paul, Matthaios, Dimitris, Oikonomou, Panagoula, Nikolaou, Christina, Charalampidis, Charalampos, and Sardeli, Chrysanthi
- Published
- 2023
- Full Text
- View/download PDF
9. Inhaled nintentanib, pirfenidone and macitentan for pulmonary fibrosis: a laboratory experiment.
- Author
-
Zarogoulidis, Paul, Petridis, Dimitris, Huang, Haidong, Bai, Chong, Oikonomou, Panagoula, Nikolaou, Christina, Matthaios, Dimitris, Perdikouri, Eleni-Isidora, Papadopoulos, Vasilis, Petanidis, Savvas, Kosmidis, Christoforos, Charalampidis, Charalampos, Hohenforst-Schmidt, Wolfgang, Kougkas, Nikos, and Sardeli, Chrysanthi
- Published
- 2023
- Full Text
- View/download PDF
10. Epithelial Ovarian Cancer: A Five Year Review.
- Author
-
Arnaoutoglou, Christos, Dampala, Kalliopi, Anthoulakis, Christos, Papanikolaou, Evangelos G., Tentas, Ioannis, Dragoutsos, Georgios, Machairiotis, Nikolaos, Zarogoulidis, Paul, Ioannidis, Aristeidis, Matthaios, Dimitris, Perdikouri, Eleni I., Giannakidis, Dimitrios, Sardeli, Chrysanthi, Petousis, Stamatios, Oikonomou, Panagoula, Nikolaou, Christina, Charalampidis, Charalampos, and Sapalidis, Konstantinos
- Subjects
OVARIAN epithelial cancer ,STEM cell treatment ,CANCER chemotherapy ,COMBINATION drug therapy ,OVARIAN cancer - Abstract
Ovarian cancer is a malignant disease that affects thousands of patients every year. Currently, we use surgical techniques for early-stage cancer and chemotherapy treatment combinations for advanced stage cancer. Several novel therapies are currently being investigated, with gene therapy and stem cell therapy being the corner stone of this investigation. We conducted a thorough search on PubMed and gathered up-to-date information regarding epithelial ovarian cancer therapies. We present, in the current review, all novel treatments that were investigated in this field over the past five years, with a particular focus on local treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. Positron Emission-Computed Tomography, Cryobiopsy versus Bronchoalveolar Lavage and Computed Tomography Findings for Interstitial Lung Disease: A Long-Term Follow-Up.
- Author
-
Zarogoulidis, Paul, Matthaios, Dimitris, Huang, Haidong, Bai, Chong, Hohenforst-Schmidt, Wolfgang, Porpodis, Konstantinos, Petridis, Dimitris, Pigakis, Konstantinos, Kougkas, Nikolaos, Oikonomou, Panagoula, Nikolaou, Christina, Hatzibougias, Dimitris, and Sardeli, Chrysanthi
- Subjects
INTERSTITIAL lung diseases ,COMPUTED tomography ,BRONCHOALVEOLAR lavage ,POSITRONS ,TOMOGRAPHY ,SURVIVAL rate - Abstract
Background and Objectives: Interstitial lung diseases have always been an issue for pulmonary and rheumatology physicians. Computed tomography scans with a high-resolution protocol and bronchoalveolar lavage have been used along with biochemical blood tests to reach a diagnosis. Materials and Methods: We included 80 patients in total. First, all patients had their diagnosis with computed tomography of the thorax, serological/ immunological blood tests and bronchoalveolar lavage. However; after 3 months, all were divided into 2 groups: those who had bronchoalveolar lavage again and those who had cryobiopsy instead of bronchoalveolar lavage (40/40). Positron emission-computed tomography was also performed upon the first and second diagnosis. The patients' follow-up was 4 years from diagnosis. Results: Patients suffered most from chronic obstructive pulmonary disease (56, 70%), while lung cancer was rarely encountered in the sample (7, 9.75%). Age distribution ranged between 53 and 68 years with a mean value of 60 years. The computed tomography findings revealed 25 patients with typical diagnosis (35.2%), 17 with interstitial pulmonary fibrosis (23.9%) and 11 with probable diagnosis (11%). The cryobiopsy technique led to a new diagnosis in 28 patients (35% of the total sample). Patients who had a new diagnosis with cryobiopsy had a mean survival time of 710 days (<1460). Positron emission-computed tomography SUV uptake was positively associated with the cryobiopsy technique/new disease diagnosis and improved all respiratory functions. Discussion: Positron emission-computed tomography is a tool that can be used along with respiratory functions for disease evaluation. Conclusions: Cryobiopsy is a safe tool for patients with interstitial lung disease and can assist in the diagnosis of interstitial lung diseases. The survival of patients was increased in the cryobiopsy group versus only bronchoalveolar lavage for disease diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Deferoxamine decreases the excitatory amino acid levels and improves the histological outcome in the hippocampus of neonatal rats after hypoxia–ischemia
- Author
-
Papazisis, Georgios, Pourzitaki, Chryssa, Sardeli, Chrysanthi, Lallas, Aimilios, Amaniti, Ekaterini, and Kouvelas, Dimitrios
- Published
- 2008
- Full Text
- View/download PDF
13. A health condition index for assessing disease progression.
- Author
-
Petridis, Dimitris, Matthaios, Dimitris, Christakidis, Vaggelis, Sardeli, Chrysanthi, Freitag, Lutz, Huang, Haidong, and Zarogoulidis, Paul
- Published
- 2022
- Full Text
- View/download PDF
14. [alpha]-MSH prevents impairment in renal function and dysregulation of AQPs and Na-K-ATPase in rats with bilateral ureteral obstruction
- Author
-
Li, Chunling, Shi, Yimin, Wang, Weidong, Sardeli, Chrysanthi, Kwon, Tae-Hwan, Thomsen, Klaus, Jonassen, Thomas, Djurhuus, Jens Christian, Knepper, Mark A., Nielsen, Soren, and Frokiver, Jorgen
- Subjects
Melanocytes -- Research ,Urinary tract infections -- Care and treatment ,Adenosine triphosphatase -- Research ,Biological sciences - Abstract
The purpose of this study was to evaluate the effects of the anti-inflammatory hormone [alpha]-melanocyte-stimulating hormone ([alpha]-MSH) treatment on renal function and expression of aquaporins (AQPs) and Na-K-ATPase in the kidney in response to 24 h of bilateral ureteral obstruction (BUO) or release of BUO (BUO-R). In rats with 24-h BUO, immunoblotting revealed that downregulation of AQP2 and AQP3 was attenuated (AQP2:38 [+ or -] 5 vs. 13 [+ or -] 4%; AQP3:44 [+ or -] 3 vs. 19 [+ or -] 4% of sham levels; P < 0.05), whereas downregulation of Na-K-ATPase was prevented by [alpha]-MSH treatment (Na-K-ATPase: 94 [+ or -] 7 vs. 35 [+ or -] 5% of sham levels; P < 0.05). Immunocytochemistry confirmed the changes in AQP1 and Na-K-ATPase expression. Renal tubular cell apoptosis was confirmed in BUO kidneys, and [alpha]-MSH treatment virtually completely abolished apoptosis. Furthermore, we measured glomerular filtration rate (GFR) and effective renal plasma flow (ERPF), respectively. Forty-eight hours after BUO-R demonstrated that [alpha]-MSH treatment almost completely prevented the decrease in GFR (nontreated: 271 [+ or -] 50; [alpha]-MSH: 706 [+ or -] 85; sham: 841 [+ or -] 105 [micro]1*[min.sup.-l]*100 g body [wt.sup.-1], P < 0.05) and ERPF (nontreated: 1,139 [+ or -] 217; [alpha]-MSH: 2,598 [+ or -] 129; sham: 2,633 [+ or -] 457 [micro]1*[min.sup.-l]*100 g body [wt.sup.-1], P < 0.05). [alpha]-MSH treatment also partly prevented the downregulation of AQP1 and Na-K-ATPase expression in rats after BUO-R for 48 h. In conclusion, [alpha]-MSH treatment significantly prevents impairment in renal function and also prevents downregulation of AQP2, AQP3, and Na-K-ATPase during BUO or AQP1 and Na-K-ATPase after BUO-R, demonstrating a marked renoprotective effect of [alpha]-MSH treatment in conditions with urinary tract obstruction. urinary tract obstruction; water channels; sodium pump; urinary concentrating defect
- Published
- 2006
15. Factors Affecting the Nuclei in Newborn and Children.
- Author
-
Arnaoutoglou, Christos, Keivanidou, Anastasia, Dragoutsos, Georgios, Tentas, Ioannis, Meditskou, Soultana, Zarogoulidis, Paul, Matthaios, Dimitrios, Sardeli, Chrysanthi, Ioannidis, Aris, Perdikouri, Eleni Isidora, and Giannopoulos, Andreas
- Published
- 2022
- Full Text
- View/download PDF
16. Surgical Treatment of Endometriosis
- Author
-
Michalopoulos, George, Makris, Vassilios, Daniilidis, Angelos, Sardeli, Chrysanthi, Dinas, Konstantinos, Giannoulis, Charilaos, and Loufopoulos, P. D.
- Published
- 2012
17. Endometriosis: The Role of Pharmacotherapy
- Author
-
Sardeli, Chrysanthi, Daniilidis, Angelos, Goulas, Antonios, Papazisis, Georgios, Kouvelas, Dimitrios, and Tzafettas, John
- Published
- 2012
18. Effect of Early Compared With Delayed Enteral Nutrition on Endocrine Function in Patients With Traumatic Brain Injury: An Open-Labeled Randomized Trial
- Author
-
Chourdakis, Michael, Kraus, Michaela M., Tzellos, Thrasivoulos, Sardeli, Chrysanthi, Peftoulidou, Maria, Vassilakos, Dimitrios, and Kouvelas, Dimitrios
- Published
- 2012
- Full Text
- View/download PDF
19. Outcome of site-specific fascia repair for rectocele
- Author
-
SARDELI, CHRYSANTHI, AXELSEN, SUSANNE M., KJÆR, DANIEL, and BEK, KARL M.
- Published
- 2007
- Full Text
- View/download PDF
20. Long Term Respiratory Follow-Up for COVID-19 Patients a Multicenter Study.
- Author
-
BURSAC, DALIBORKA, PETRIDIS, DIMITRIS, ZARIC, BOJAN, KOVACEVIC, TOMI, STOJSIC, VLADIMIR, SARCEV, TATJANA, HUANG, HAIDONG, HOHENFORST-SCHMIDT, CHONG BAI3,WOLFGANG, KOSMIDIS, CHRISTOFOROS, SAPALIDIS, KONSTANTINOS, ROMANIDIS, KONSTANTINOS, COURCOUTSAKIS, NIKOLAOS, LALLAS, AIMILIOS, TSAKALDIMIS, GIORGOS, CHATZIMICHAEL, KYRIAKOULA, SARDELI, CHRYSANTHI, MATTHAIOS, DIMITRIS, ZAROGOULIDIS, PAUL, and KARAPANTZOU, CHRYSANTHI
- Subjects
COVID-19 ,SYMPTOMS ,COVID-19 testing ,VIRUS diseases ,DIAGNOSTIC use of polymerase chain reaction - Abstract
Background: The first wave of the COVID-19 pandemic initiated officially in October 2020. Since then several observations have been made regarding the disease and its symptoms. Patients and Methods: We included eighty seven in our observational study. Our main aim was to investigate their long term respiratory follow-up in correlation with their initial radiological and laboratory findings and values. The nose swab PCR test for COVID-19 was used for diagnosis. Patients were monitored at 3 and 6 months after their hospital reception whereas basic parameters of health condition (smoking, PO2, SPO2, WBC, CXR, CRP, intercurrent findings, days of nursing, colchicine administration) in joint with gender and age were recorded. Results: Males seem more susceptible to the viral disease than females in a ratio 1,8:1. The parameters FEV1 and FVC (as % relative changes) were not affected, apart from the DLCO to which CRP (in loge+1 transformation) and SPO2 showed a statistically significant effect. Conclusion: None of these patients were intubated, or admitted to the intensive care unit. The respiratory function is affected by the virus and the effect is reversed within the first three months. Males are more affected and the radiological and laboratory findings are associated with the respiratory functions. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
21. Renal aquaporins and sodium transporters with special focus on urinary tract obstruction
- Author
-
FRØKIÆR, JORGEN, LI, CHUNLING, SHI, YIMIN, JENSEN, ANJA, PRÆTORIUS, HELLE, HANSEN, HELLE, TOPCU, OGUZ, SARDELI, CHRYSANTHI, WANG, WEIDONG, KWON, TAE-HWAN, and NIELSEN, SØREN
- Published
- 2003
22. Mechanisms producing Tinnitus. An experimental model.
- Author
-
Pavlidis, Pavlos, Papadopoulou, Kyriaki, Tseriotis, Vasilis Spyridon, Karachrysafi, Sofia, Sardeli, Chrysanthi, Gouveris, Haralampos, Papamitsou, Theodora, Sioga, Antonia, and Kouvelas, Dimitrios
- Published
- 2024
- Full Text
- View/download PDF
23. Antidepressants on Multiple Sclerosis: A Review of In Vitro and In Vivo Models.
- Author
-
Stamoula, Eleni, Siafis, Spyridon, Dardalas, Ioannis, Ainatzoglou, Alexandra, Matsas, Alkis, Athanasiadis, Theodoros, Sardeli, Chrysanthi, Stamoulas, Konstantinos, and Papazisis, Georgios
- Subjects
MULTIPLE sclerosis ,ANTIDEPRESSANTS ,DELAYED onset of disease ,CELL differentiation ,DRUG efficacy ,IMMUNOREGULATION - Abstract
Background: Increased prevalence of depression has been observed among patients with multiple sclerosis (MS) and correlated with the elevated levels of proinflammatory cytokines and the overall deregulation of monoaminergic neurotransmitters that these patients exhibit. Antidepressants have proved effective not only in treating depression comorbid to MS, but also in alleviating numerous MS symptoms and even minimizing stress-related relapses. Therefore, these agents could prospectively prove beneficial as a complementary MS therapy. Objective: This review aims at illustrating the underlying mechanisms involved in the beneficial clinical effects of antidepressants observed in MS patients. Methods: Through a literature search we screened and comparatively assessed papers on the effects of antidepressant use both in vitro and in vivo MS models, taking into account a number of inclusion and exclusion criteria. Results: In vitro studies indicated that antidepressants promote neural and glial cell viability and differentiation, reduce proinflammatory cytokines and exert neuroprotective activity by eliminating axonal loss. In vivo studies confirmed that antidepressants delayed disease onset and alleviated symptoms in Experimental Autoimmune Encephalomyelitis (EAE), the most prevalent animal model of MS. Further, antidepressant agents suppressed inflammation and restrained demyelination by decreasing immune cell infiltration of the CNS. Conclusion: Antidepressants were efficient in tackling numerous aspects of disease pathophysiology both in vitro and in vivo models. Given that several antidepressants have already proved effective in clinical trials on MS patients, the inclusion of such agents in the therapeutic arsenal of MS should be seriously considered, following an individualized approach to minimize the adverse events of antidepressants in MS patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
24. Personalized Approach to Tissue and Liquid Biopsy after Failure of First-Line EGFR-TKIs: Is There an Issue When Tissue Is Not the Issue? A Case Series.
- Author
-
Bursac, Daliborka, Zarić, Bojan, Kovačević, Tomi, Stojšić, Vladimir, Vagionas, Anastasios, Boukovinas, Ioannis, Tsakiridis, Kosmas, Kosmidis, Christoforos, Sapalidis, Konstantinos, Romanidis, Konstantinos, Courcoutsakis, Nikolaos, Matthaios, Dimitris, Zarogoulidis, Paul, Sardeli, Chrysanthi, and Sekerus, Vanesa
- Subjects
EPIDERMAL growth factor receptors ,PROTEIN-tyrosine kinase inhibitors ,BIOPSY - Abstract
Traditionally, tissue availability from rebiopsy is a prerequisite for adequate sequencing of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in therapy for advanced-stage lung cancer. Tissue biopsy truly is the gold standard for genetic analyses, but in some cases, such as with inadequate localization of the lesion or a patient's inadequate performance status, comorbidities, or unwillingness to undergo an invasive procedure, liquid biopsy-based ctDNA analysis can be a noninvasive alternative approach. However, in some cases the gold standard might not shine that much. It is known that tumor heterogeneity or an inadequate amount of tissue might significantly interfere with the results of testing. In this paper, we present cases of patients with a negative tissue biopsy but a positive liquid biopsy which identified coexisting T790M mutation. These results enabled adequate sequencing and treatment with third-line EGFR-TKIs. Such possibilities stress the need to individualize testing for driver mutations in cases where it is clinically highly indicated. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
25. PD-L1 and standardized uptake value expression in lung cancer: a possible connection for efficient early lung cancer treatment.
- Author
-
Zarogoulidis, Paul, Sardeli, Chrysanthi, Christakidis, Vagelis, Hohenforst-Schmidt, Wolfgang, Huang, Haidong, Kosmidis, Christoforos, Vagionas, Anastasios, Baka, Sofia, Tsakiridis, Kosmas, Perdikouri, Eleni-Isidora, Romanidis, Konstantinos, and Sapalidis, Konstantinos
- Published
- 2021
- Full Text
- View/download PDF
26. Second-line afatinib administration in an elderly patient with squamous cell carcinoma
- Author
-
Hohenforst-Schmidt,Wolfgang, Zarogoulidis,Paul, Steinheimer,Michael, Benhassen,Naim, Sardeli,Chrysanthi, Stalikas,Nikos, Toitou,Melpomeni, and Huang,Haidong
- Subjects
Therapeutics and Clinical Risk Management - Abstract
Wolfgang Hohenforst-Schmidt,1 Paul Zarogoulidis,2 Michael Steinheimer,1 Naim Benhassen,3 Chrysanthi Sardeli,4 Nikos Stalikas,2 Melpomeni Toitou,2 Haidong Huang5 1Sana Clinic Group Franken, Department of Cardiology/Pulmonology/Intensive Care/Nephrology, “Hof” Clinics, University of Erlangen, Hof, Germany; 2Pulmonary Department – Oncology Unit, “G Papanikolaou” General Hospital, Thessaloniki, Greece; 3Medical Clinic I, “Fuerth” Hospital, University of Erlangen, Fuerth, Germany; 4Department of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece; 5Department of Respiratory and Critical Care Medicine, Changhai Hospital/First Affiliated Hospital of the Secondary Military Medical University, Shanghai, China Introduction: The majority of cases of lung cancer are still diagnosed at a late stage. At this stage, palliative therapeutic options including nonspecific cytotoxic drugs, targeted therapy, or immunotherapy can be utilized. In 2016, immunotherapy was approved in Europe for squamous cell carcinoma and adenocarcinoma. Moreover, afatinib was also approved as second-line therapy for squamous cell carcinoma. Case report: This article presents a case of a 76-year-old male with squamous cell carcinoma who received nab-paclitaxel as first-line therapy, and his treatment was switched to the tyrosine kinase inhibitor afatinib (40 mg) after disease progression with left lung atelectasis. After receiving afatinib for only 28 days, the atelectasis resolved. No adverse effects were observed from the afatinib therapy. Discussion: In this case, afatinib 40 mg proved to be an effective alternative treatment for an elderly patient. Treatment choice should be based on the performance status of the patient, cost-effectiveness, and drug treatment guidelines. Keywords: lung cancer, EGFR, afatinib
- Published
- 2017
27. Use of porcine small intestinal submucosa in the surgical treatment of recurrent rectocele in a patient with Ehlers–Danlos syndrome type III
- Author
-
Sardeli, Chrysanthi, Axelsen, Susanne M., and Bek, Karl M.
- Published
- 2005
- Full Text
- View/download PDF
28. Acute pneumothorax due to immunotherapy administration in non-small cell lung cancer
- Author
-
Sardeli, Chrysanthi, Zarogoulidis, Paul, Romanidis, Konstantinos, Oikonomou, Panagoula, Sapalidis, Konstantinos, Huang, Haidong, Bai, Chong, Hohenforst-Schmidt, Wolfgang, Tsakiridis, Kosmas, Zaric, Bojan, Perin, Branislav, Ioannidis, Aris, Baka, Sofia, Drevelegas, Konstantinos, Kosmidou, Maria, and Kosmidis, Christoforos
- Published
- 2020
- Full Text
- View/download PDF
29. Beware of hemopneumothorax following core needle breast biopsy
- Author
-
Schizas, Nikos, Lazopoulos, Achileas, Krimiotis, Dimitris, Rallis, Thomas, Paliouras, Dimitris, Gogakos, Apostolos, Chatzinikolaou, Fotis, Sarafis, Pavlos, Domeyer, Philip, Zarogoulidis, Paul, Tsiouda, Theodora, Sardeli, Chrysanthi, Laskou, Stella, Koulouris, Charilaos, Pavlidis, Efstathios, Mantalobas, Stylianos, Giannakidis, Dimitris, Kesisoglou, Isaak, Sapalidis, Konstantinos, and Barbetakis, Nikos
- Published
- 2018
- Full Text
- View/download PDF
30. Esophagus lyomyoma diagnosed with convex endobronchial ultrasound (EBUS)
- Author
-
Zarogoulidis, Paul, Laskou, Stella, Katsaounis, Athanasios, Pavlidis, Efstathios, Giannakidis, Dimitrios, Koulouris, Charilaos, Mantalovas, Stylianos, Kougioumtzi, Ioanna, Katsikogiannis, Nikolaos, Konstantinou, Fotis, Hohenforst-Schmidt, Wolfgang, Huang, Haidong, Bai, Chong, Euthimiou, Alkis, Hatzibougas, Dimitris, Fitili, Iota, Sardeli, Chrysanthi, Rapti, Aggeliki, Kesisoglou, Isaak, and Sapalidis, Konstantinos
- Published
- 2018
- Full Text
- View/download PDF
31. Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases
- Author
-
Zarogoulidis, Paul, Chinelis, Panos, Athanasiadou, Anastasia, Tsiouda, Theodora, Trakada, Georgia, Kallianos, Anastasios, Veletza, Lemonia, Hatzibougias, Dimitris, Mihalopoulou, Electra, Goupou, Eirini, Kosmidis, Christoforos, Sardeli, Chrysanthi, Huang, Haidong, and Hohenforst-Schmidt, Wolfgang
- Published
- 2017
- Full Text
- View/download PDF
32. Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series
- Author
-
Zarogoulidis, Paul, Rapti, Aggeliki, Sardeli, Chrysanthi, Chinelis, Panagiotis, Athanasiadou, Anastasia, Paraskevaidou, Katerina, Kallianos, Anastasios, Veletza, Lemonia, Trakada, Georgia, Hohenforst-Schmidt, Wolfgang, and Huang, Haidong
- Published
- 2017
- Full Text
- View/download PDF
33. The Role of Sarcosine, Uracil, and Kynurenic Acid Metabolism in Urine for Diagnosis and Progression Monitoring of Prostate Cancer.
- Author
-
Gkotsos, Georgios, Virgiliou, Christina, Lagoudaki, Ioanna, Sardeli, Chrysanthi, Raikos, Nikolaos, Theodoridis, Georgios, and Dimitriadis, Georgios
- Subjects
PROSTATE cancer ,DIAGNOSIS ,PROSTATE cancer patients ,URACIL ,DISEASE progression ,BIOMARKERS - Abstract
The aim of this pilot study is to evaluate sarcosine, uracil, and kynurenic acid in urine as potential biomarkers in prostate cancer detection and progression monitoring. Sarcosine, uracil, and kynurenic acid were measured in urine samples of 32 prostate cancer patients prior to radical prostatectomy, 101 patients with increased prostate-specific antigen prior to ultrasonographically-guided prostatic biopsy collected before and after prostatic massage, and 15 healthy volunteers (controls). The results were related to histopathologic data, Gleason score, and PSA (Prostate Specific Antigen). Metabolites were measured after analysis of urine samples with Ultra-High Performance Liquid Chromatography coupled to tandem mass spectrometry (UPLC-MS/MS) instrumentation. Multivariate, nonparametric statistical tests including receiver operating characteristics analyses, one-way analysis of variance (Kruskal-Wallis test), parametric statistical analysis, and Pearson correlation, were performed to evaluate diagnostic performance. Decreased median sarcosine and kynurenic acid and increased uracil concentrations were observed for patients with prostate cancer compared to participants without malignancy. Results showed that there was no correlation between the concentration of the studied metabolites and the cancer grade (Gleason score <7 vs. ≥7) and the age of the patients. Evaluation of biomarkers by ROC (Receiving Operating Characteristics) curve analysis showed that differentiation of prostate cancer patients from participants without malignancy was not enhanced by sarcosine or uracil levels in urine. In contrast to total PSA values, kynurenic acid was found a promising biomarker for the detection of prostate cancer particularly in cases where collection of urine samples was performed after prostatic massage. Sarcosine and uracil in urine samples of patients with prostate cancer were not found as significant biomarkers for the diagnosis of prostate cancer. None of the three metabolites can be used reliably for monitoring the progress of the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
34. Ν-Methyl-D-aspartate antagonists and their role in limiting ototoxic phenomena.
- Author
-
Pavlidis, Pavlos, Papadopoulou, Kyriaki, Tseriotis, VasiliosSpyridon, Karachrysafi, Sophia, Sardeli, Chrysanthi, Gouveris, Haralampos, Malliou, Faye, Papamitsou, Theodora, Sioga, Antonia, and Kouvelas, Dimitrios
- Published
- 2023
- Full Text
- View/download PDF
35. α-MSH prevents impairment in renal function and dysregulation of AQPs and Na-K-ATPase in rats with bilateral ureteral obstruction.
- Author
-
Chunling Li, Ylmin Shi, Weidong Wang, Sardeli, Chrysanthi, Tae-Hwan Kwon, Thomsen, Klaus, Jonassen, Thomas, Djurhuus, Jens Christian, Knepper, Mark A., Nielsen, Søren, and Fr∅kær, Jørgen
- Subjects
HORMONES ,AQUAPORINS ,KIDNEYS ,URETERIC obstruction ,IMMUNOCYTOCHEMISTRY ,ADENOSINE triphosphatase - Abstract
The purpose of this study was to evaluate the effects of the anti-inflammatory hormone α-melanocyte-stimulating hormone (α-MSH) treatment on renal function and expression of aquaporins (AQPs) and Na-K-ATPase in the kidney in response to 24 h of bilateral ureteral obstruction (BUO) or release of BUO (BUO-R). In rats with 24-h BUO, immunoblotting revealed that downregulation of AQP2 and AQP3 was attenuated (AQP2: 38 ± 5 vs. 13 ± 4%; AQP3: 44 ± 3 vs. 19 ± 4% of sham levels; P < 0.05), whereas downregulation of Na-K-ATPase was prevented by α-MSH treatment (Na-K-ATPase: 94 ± 7 vs. 35 ± 5% of sham levels; P < 0.05). Immunocytochemistry confirmed the changes in AQP1 and Na-K-ATPase expression. Renal tubular cell apoptosis was confirmed in BUO kidneys, and α-MSH treatment virtually completely abolished apoptosis. Furthermore, we measured glomerular filtration rate (GFR) and effective renal plasma flow (ERPF), respectively. Forty-eight hours after BUO-R demonstrated that α-MSH treatment almost completely prevented the decrease in GFR (nontreated: 271 ± 50; a-MSH: 706 ± 85; sham: 841 ± 105 μl·min
-1 ·100 g body wt-1 , P < 0.05) and ERPF (nontreated: 1,139 ± 217; α-MSH: 2,598 ± 129; sham: 2,633 ± 457 μl·min-1 ·100 g body wt-1 , P < 0.05). α-MSH treatment also partly prevented the downregulation of AQP1 and Na-K-ATPase expression in rats after BUO-R for 48 h. In conclusion, α-MSH treatment significantly prevents impairment in renal function and also prevents downregulation of AQP2, AQP3, and Na-K-ATPase during BUO or AQP1 and Na-K-ATPase after BUO-R, demonstrating a marked renoprotective effect of α-MSH treatment in conditions with urinary tract obstruction. [ABSTRACT FROM AUTHOR]- Published
- 2006
- Full Text
- View/download PDF
36. Renal aquaporins and sodium transporters with special focus on urinary tract obstruction.
- Author
-
Frokiaer, Jorgen, Chunling Li, Yimin Shi, Jensen, Anja, Praetorius, Helle, Hansen, Helle, Topcu, Oguz, Sardeli, Chrysanthi, Weidong Wang, Tae-Hwan Kwon, and Nielsen, Soren
- Subjects
AQUAPORINS ,SODIUM channels ,URINARY obstructions ,KIDNEYS ,UROLOGY - Abstract
Deals with a study which reviewed the role of renal aquaporins (AQP2) and sodium transporters and channels, and their role for the impaired urinary concentrating capacity in response to urinary tract obstruction. Background on renal aquaporins; Role of AQP2 in water balance regulation; Discussion on renal sodium transporters and channels.
- Published
- 2003
37. Inhaled Cisplatin for NSCLC: Facts and Results.
- Author
-
Kosmidis, Christoforos, Sapalidis, Konstantinos, Zarogoulidis, Paul, Sardeli, Chrysanthi, Koulouris, Charilaos, Giannakidis, Dimitrios, Pavlidis, Efstathios, Katsaounis, Athanasios, Michalopoulos, Nikolaos, Mantalobas, Stylianos, Koimtzis, Georgios, Alexandrou, Vyron, Tsiouda, Theodora, Amaniti, Aikaterini, and Kesisoglou, Issak
- Subjects
NON-small-cell lung carcinoma ,IMMUNOTHERAPY ,CISPLATIN ,ALKYLATING agents ,ANTINEOPLASTIC agents - Abstract
Although we have new diagnostic tools for non-small cell lung cancer, diagnosis is still made in advanced stages of the disease. However, novel treatments are being introduced in the market and new ones are being developed. Targeted therapies and immunotherapy have brought about a bloom in the treatment of non-small cell lung cancer. Still we have to find ways to administer drugs in a more efficient and safe method. In the current review, we will focus on the administration of inhaled cisplatin based on published data. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
38. Genes' Interactions: A Major Contributor to the Malignant Transformation of Endometriosis.
- Author
-
Sapalidis, Konstantinos, Machairiotis, Nikolaos, Zarogoulidis, Paul, Vasilakaki, Sofia, Sardeli, Chrysanthi, Koimtzis, George, Pavlidis, Efstathios, Katsaounis, Athanasios, Giannakidis, Dimitrios, Michalopoulos, Nikolaos, Mantalobas, Stylianos, Alexandrou, Vyron, Koulouris, Charilaos, Amaniti, Aikaterini, and Kesisoglou, Isaak
- Subjects
ENDOMETRIOSIS ,CANCER cells ,GENOMES ,PHENOTYPES - Abstract
The genetic and epigenetic factors that contribute to the malignant transformation of endometriosis are still under investigation. The objective of the present study was to investigate the genetic link between endometriosis and cancer by examining and correlating the latest clinical observations with biological experimental data. We collected updated evidence about the genetic relationship between endometriosis and cancers by conducting a comprehensive search of PubMed and Scopus databases, focusing on the papers published between January 2018 and January 2019. New insights into the mechanism of the malignant transformation of endometriosis have been published recently. The use of state-of-the-art techniques and methods, such as the genome-wide association study analysis and the weighted gene co-expression analysis, have significantly altered our understanding of the association between endometriosis and endometriosis-associated cancer development. Interestingly, the interactions formed between genes seem to play a pivotal role in the phenotypic expression of mutations. Therefore, the effect of single nucleotide polymorphisms and the function of the expression quantitative trait loci on genes' expression have been the subject of many recent works. In addition, it has been discovered that genes, the mutations of which have been related to the development of endometriosis, play a role as hub genes. This may lead to new areas of research for understanding the mechanism of malignant transformation of the disease. Significant steps forward have been made towards the identification of factors that control the malignant transformation of endometriosis. Still, due to rarity of the event, a better-organized scheme for sampling on a global level should be adopted. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
39. Pregabalin abuse after past substance-seeking behavior.
- Author
-
Papazisis, Georgios, Garyfallos, Georgios, Sardeli, Chrysanthi, and Kouvelas, Dimitrios
- Published
- 2013
- Full Text
- View/download PDF
40. Chronic Obstructive Pulmonary Disease and Non-Small Cell Lung Cancer an association.
- Author
-
Zarogoulidis P, Oikonomidou R, Petridis D, Huang H, Bai C, Perdokouri EI, Vagionas A, Hohenforst-Schmidt W, Kosmidis C, Sapalidis K, Oikonomou P, Nikolaou C, Charalampidis C, Matthaios D, Pataka A, and Sardeli C
- Abstract
Objectives: Lung cancer is known to be associated with chronic obstructive pulmonary disease. Moreover; nutritional status is associated with chronic obstructive disease treatment and lung cancer. Our aim was to evaluate the interaction of the COPD status and treatment of non-small cell lung cancer. Methods: Eighty-two patients were enrolled in our multicenter study. Chronic obstructive disease stage, spirometry and treatment was recorded along with the treatment and Body Mass Index (BMI), Mediterranian Diet Score, Pack Years, Basic Metabolsim (RMR) (kcal/day), VO₂ (ml/min), Ve (lt/min) and Physical Activity. The statistical analysis was performed using the JMP 14.3 (SAS Inc 2018) software. Results: The drug pairs showed a steady and unchanged by time health condition for 48 patients. Overall, 31 patients were recorded with worse COPD health conditions. The one-way ANOVA clearly indicated that chemotherapy induced the best FEV
1 -difference conditions with a positive effect of 8.56 mean FEV volume, the combined treatment simply did not have an effect (-0.9), while immunotherapy and patients receiving radiation decreased their FEV1 volume down to -4.23 and -5.15 mean values. Conclusions: Patients receiving chemotherapy alone had their chronic obstructive disease improved with less drugs and exacerbations, while patients receiving immunotherapy had their chronic obstructive disease stable, while all other treatment combinations worsened the patients chronic obstructive disease. Nutritional status did not affect the chronic obstructive disease of these patients in any way., Competing Interests: Competing Interests: The authors have declared that no competing interest exists., (© The author(s).)- Published
- 2024
- Full Text
- View/download PDF
41. Nebulisation of Paclitaxel, Sotatercept and Iloprost for pulmonary hypertension for lung cancer. From In vitro to In vivo .
- Author
-
Zarogoulidis P, Petridis D, Huang H, Bai C, Pitsiou G, Matthaios D, Perdikouri EI, Papadopoulos V, Petanidis S, Kosmidis C, Hohenforst-Schmidt W, Porpodis K, Kougas N, Oikonomou P, Nikolaou C, Charalampidis C, and Sardeli C
- Abstract
Background: Pulmonary hypertension is common symptom among several diseases. The consequences are severe for several organs. Pulmonary hypertension is usually under-diagnosed and the main symptom observed is dyspnea with or without exercise. Currently we have several treatment modalities administered orally, via inhalation, intravenously and subcutaneously. In advanced disease then heart or lung transplantation is considered. The objective of the study was to investigate the optimum method of aerosol production for the drugs: iloprost, paclitaxel and the novel sotatercept. Materials and Methods: In our experiment we used the drugs iloprost, paclitaxel and the novel sotatercept, in an experimental concept of nebulization. We performed nebulization experiments with 3 jet nebulizers and 3 ultrasound nebulizers with different combinations of residual cup designs, and residual cup loadings in order to identify which combination produces droplets of less than 5μm in mass median aerodynamic diameter. Results: We concluded that paclitaxel cannot produce small droplets and is also still very greasy and possible dangerous for alveoli. However; iloprost vs sotatercept had smaller droplet size formation at both inhaled technologies (1.37<2.23 and 1.92<3.11, jet and ultrasound respectively). Moreover; residual cup designs C and G create the smallest droplet size in both iloprost and sotatercept. There was no difference for the droplet formation between the facemask and cone mouthpieces. Discussion: Iloprost and sotatercept can be administered as aerosol in any type of nebulisation system and they are both efficient with the residual cups loaded with small doses of the drug (2.08 and 2.12 accordingly)., Competing Interests: Competing Interests: The authors have declared that no competing interest exists., (© The author(s).)
- Published
- 2024
- Full Text
- View/download PDF
42. Sentinel Lymph Node Staging in Early-Stage Cervical Cancer: A Comprehensive Review.
- Author
-
Margioula-Siarkou C, Almperis A, Gullo G, Almperi EA, Margioula-Siarkou G, Nixarlidou E, Mponiou K, Papakotoulas P, Sardeli C, Guyon F, Dinas K, and Petousis S
- Abstract
Cervical cancer (CC) continues to be a significant global public health concern, even with preventive measures in place. In women with early-stage CC, the status of lymph nodes is of paramount importance, not only for the final prognosis but also for determining the best therapeutic strategy. According to main international guidelines, pelvic full lymphadenectomy (PLND) is recommended for lymph node staging. However, in these early stages of CC, sentinel lymph node biopsy (SLNB) has emerged as a precise technique for evaluating lymph node involvement, improving its morbidity profile. We performed a literature review through PubMed articles about progress on the application of SLNB in women with early-stage CC focusing on the comparison with PET/CT and PLND in terms of oncological outcomes and diagnostic accuracy. While the superiority of SLNB is clear compared to radiologic modalities, it demonstrates no clear oncologic inferiority over PLND, given the higher detection rate of positive lymph nodes and predominance of no lymph node recurrences. However, due to a lack of prospective evidence, particularly concerning long-term oncological safety, SLNB is not the current gold standard. With careful patient selection and adherence to straightforward protocols, a low false-negative rate can be ensured. The aim of the ongoing prospective trials is to address these issues.
- Published
- 2023
- Full Text
- View/download PDF
43. Endobronchial Radiofrequency Ablation for pulmonary nodules with Radial-Ebus and Navigation: Pros and Cons.
- Author
-
Zarogoulidis P, Hohenforst-Schmidt W, Chen W, Porpodis K, Kosmidis C, Kotsakis A, Perdikouri EI, Tolis C, Ioannidis A, Sapalidis K, Matthaios D, Giannakidis D, Oikonomou P, Nikolaou C, Papadopoulos V, Sardeli C, Charalampidis C, Petanidis S, Bai C, and Huang H
- Abstract
Introduction: Pulmonary nodules are common in the everyday clinical practice. There is always a diagnostic issue with this imaging finding. Based on the size we can use a variety of imaging and diagnostic techniques. Moreover; in the case of primary lung cancer or metastasis we can use radiofrequency ablation endobronchially. Patients and Methods: We used the radial-endobronchial ultrasound with C-arm and Archemedes, Bronchus electromagnetic navigation in order to acquire biopsy sample and we also used rapid on-site evaluation as a rapid diagnosis for pulmonary nodules. After rapid diagnosis we used the radiofrequency ablation catheter in order to ablate central pulmonary nodules. Results: Both techniques provide efficient navigation, however, with the Bronchus system less time is needed. The new radiofrequency ablation catheter provides efficient results in central lesions with low watts ≤40. Conclusion: We provided in our research a protocol to diagnose and treat such lesions. Future larger studies will provide more data on this subject., Competing Interests: Competing Interests: The authors have declared that no competing interest exists., (© The author(s).)
- Published
- 2023
- Full Text
- View/download PDF
44. Airway local endoscopic pharmacological treatment; current applications and future concepts.
- Author
-
Zarogoulidis P, Kosmidis C, Sapalidis K, Hohenforst-Schmidt W, Matthaios D, Tsakiridis K, Lallas A, Bai C, Huang H, Arnaoutoglou C, Ioannidis A, and Sardeli C
- Subjects
- Sirolimus, Treatment Outcome, Drug-Eluting Stents, Everolimus
- Abstract
Introduction: Local treatment of the airways and lung parenchyma has been used in clinical practice for several years for a variety of diseases., Methods: A variety of endoscopic tools for local treatment exist, especially for treating malignancies. Using these endoscopic tools, one can administer drugs specifically designed for the airways., Discussion: This article presents all locally administered treatment options and provides useful insights for future local endoscopically applied treatments., Competing Interests: The authors declare no conflict of interest., (© 2022 The Author(s). Published by IMR Press.)
- Published
- 2022
- Full Text
- View/download PDF
45. Priority of PET-CT vs CT Thorax for EBUS-TBNA 22G vs 19G: Mesothorax Lymphadenopathy.
- Author
-
Zarogoulidis P, Huang H, Hu Z, Wu N, Wang J, Petridis D, Tsakiridis K, Matthaios D, Kosmidis C, Hohenforst-Schmidt W, Tolis C, Boukovinas I, Courcoutsakis N, Nikolaidis G, Sardeli C, Bai C, and Karapantzou C
- Abstract
Introduction: Lung lesions and undiagnosed mesothorax lymphadenopathy is an issue that several doctors face in the everyday clinical practice. PET-CT and CT of the thorax are usually the first examinations to identify characteristics of the lesions before biopsy. Patients and Methods: We performed a retrospective study with 450 patients that had EBUS-TBNA with 22G, Upgraded 22G and 19G needles with and without PET-CT in order to identify the cost effeteness of performing EBUS-TBNA before or after PET-CT. All centers used the same PET-CT equipment and EBUS-TBNA system. Three types of needle were used for the endoscopy in order to identify similarities and differences for the cost-effectiveness. The costs in every center for every examination and materials were the same. Results: There were more block slices for 19G>22Gupgraded>21G>22G and there was cost-effectiveness when in general PET-CT was performed prior to biopsy of any lesion. 19G needle was more effective for lymphomas, while 22Gupgraded and 21G needles were more cost-effective when used for smaller lesions for primary lung cancer of metastatic disease. Conclusions: We have been using PET-CT and EBUS-TBNA in the everyday clinical practice according to the current guidelines for initial disease staging and re-staging. However; we can also use both in a cost effective method based on the initial radiologic findings., Competing Interests: Competing Interests: The authors have declared that no competing interest exists., (© The author(s).)
- Published
- 2021
- Full Text
- View/download PDF
46. Connection between PD-L1 expression and standardized uptake value in NSCLC: an early prognostic treatment combination.
- Author
-
Zarogoulidis P, Christakidis V, Petridis D, Sapalidis K, Kosmidis C, Vagionas A, Perdikouri EI, Hohenforst-Schmidt W, Huang H, Petanidis S, Tsakiridis K, Baka S, Romanidis K, Zaric B, Kovacevic T, Stojsic V, Sarcev T, Bursac D, Kukic B, Boukovinas I, Tolis C, and Sardeli C
- Subjects
- B7-H1 Antigen, Endoscopic Ultrasound-Guided Fine Needle Aspiration, Female, Humans, Prognosis, Carcinoma, Non-Small-Cell Lung diagnostic imaging, Lung Neoplasms diagnostic imaging
- Abstract
Objectives : Lung cancer is still diagnosed at advanced stage and early treatment initiation is needed. Therefore, we need biomarkers or clusters of information that can provide early treatment prognosis. Methods : Biopsies were acquired from 471 patients-lung masses with CT-guided biopsy, convex probe transthorasic biopsy, and EBUS-TBNA convex probe with 18 G needles and 19 G needles. Results : Standardized uptake value (SUV) measurement is associated with female, smoking status, hepatic metastasis, adenocarcinoma and programmed death-ligand 1 (PD-L1). In specific we expect that SUV ≥ 7 is associated with PD-L1 ≥ 50. Conclusions : Lung masses indifferent of size that have SUV ≥ 7 will also have PD-L1 expression ≥ 50. Also, it is likely that these patients will be female with intense smoking habit and hepar or multiple metastasis.
- Published
- 2021
- Full Text
- View/download PDF
47. Intratumoral Treatment with Chemotherapy and Immunotherapy for NSCLC with EBUS-TBNA 19G.
- Author
-
Zarogoulidis P, Hohenforst-Schmidt W, Huang H, Zhou J, Wang Q, Wang X, Xia Y, Ding Y, Bai C, Kosmidis C, Sapalidis K, Sardeli C, Tsakiridis K, Zaric B, Kovacevic T, Stojsic V, Sarcev T, Bursac D, Kukic B, Baka S, Athanasiou E, Hatzibougias D, Michalopoulou-Manoloutsiou E, Petanidis S, Drougas D, Drevelegas K, Paliouras D, Barbetakis N, Vagionas A, Freitag L, Lallas A, Boukovinas I, Petridis D, Ioannidis A, Matthaios D, Romanidis K, and Karapantzou C
- Abstract
Introduction: Immunotherapy is being used for the past five years either as first line or second line treatment with great results. Chemotherapy and radiotherapy have been also used as combination to immunotherapy to further enhance this type of treatment. Intratumoral treatment has been previously proposed as a treatment option for certain non-small cell lung cancer patients. Patients and Methods: We recruited in total seventy four patients with non-small cell lung cancer in their second line treatment who received only chemotherapy in their first line treatment with programmed death-ligand-1 ≤ 50. Only adenocarcinoma or squamous cell carcinoma, and all negative for epidermal growth factor receptor, anaplastic lymphoma kinase, proto-oncogene tyrosine-protein kinase-1 and proto-oncogene B-Raf. Data were first examined with descriptive statistics choosing frequencies for categorical variables and histograms for the continuous ones. Twenty five received only intravenous immunotherapy and forty-nine intravenous cisplatin with immunotherapy. Data were first examined with descriptive statistics choosing frequencies for categorical variables and histograms for the continuous ones. Results: The relationships between changes of performance status and disease progression were examined via a single correspondence analysis. The two-dimensional scores (coordinates) derived from the correspondence analysis were then regressed against the predictors to form distinct splits and nodes obtaining quantitative results. The best fit is usually achieved by lowering exhaustively the AICc criterion and looking in parallel the change of R
2 expecting improvements more than 5%. both types of therapy are capable of producing best ameliorative effects, when either the programmed death-ligand-1 expression or parenchymal site in joint with low pack years are present in the sampling data. Conclusions: Intratumoral treatment combination with cisplatin plus immunotherapy indifferent of nivolumab or pembrolizumab combination is an effective choice. In specific for those with endobronchial lesions. Moreover; patients with programmed death-ligand-1 ≥ 50 had their performance status and disease progression improved over the eight month observation., Competing Interests: Competing Interests: The authors have declared that no competing interest exists., (© The author(s).)- Published
- 2021
- Full Text
- View/download PDF
48. Inhaled chemotherapy adverse effects: mechanisms and protection methods.
- Author
-
Sardeli C, Zarogoulidis P, Kosmidis C, Amaniti A, Katsaounis A, Giannakidis D, Koulouris C, Hohenforst-Schmidt W, Huang H, Bai C, Michalopoulos N, Tsakiridis K, Romanidis K, Oikonomou P, Mponiou K, Vagionas A, Goganau AM, Kesisoglou I, and Sapalidis K
- Abstract
Lung cancer is still diagnosed at a late stage due to a lack of symptoms. Although there are novel therapies, many patients are still treated with chemotherapy. In an effort to reduce adverse effects associated with chemotherapy, inhaled administration of platinum analogs has been investigated. Inhaled administration is used as a local route in order to reduce the systemic adverse effects; however, this treatment modality has its own adverse effects. In this mini review, we present drugs that were administered as nebulized droplets or dry powder aerosols for non-small-cell lung cancer. We present the adverse effects and methods to overcome them., Competing Interests: Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript., (© 2020 Paul Zarogoulidis.)
- Published
- 2020
- Full Text
- View/download PDF
49. Pleurodesis and Immunotherapy in NSCLC; Medical Thoracoscopy or VATS?
- Author
-
Zarogoulidis P, Huang H, Yang M, Zhou J, Jiao Y, Wang Q, Petridis D, Sapalidis K, Sardeli C, Konsta P, Koulouris C, Michalopoulos N, Giannakidis D, Barbetakis N, Katsaounis A, Hohenforst-Schmidt W, Amaniti A, Petanidis S, Tsakiridis K, Courcoutsakis N, Goganau AM, Vagionas A, Romanidis K, Oikonomou P, Karanikas M, Katsios IN, Kesisoglou I, and Kosmidis C
- Abstract
Introduction : Immunotherapy is a treatment option for non-small cell lung cancer advanced disease. However; immunotherapy in several patients induces orogonitis and effusion in different cavities. It is up to the treating physician to understand whether there is effusion due to adverse effect or disease progression. Pleurodesis in both cases might be a solution for recurrent pleura effusion. Patients and Methods : Three hundred and thirty seven non-small cell lung cancer patients with adenocarcinoma and pleura effusion during first line immunotherapy treatment underwent medical thoracoscopy or Video assisted thoracic surgery (VATS) for pleurodesis with talk poudrage. Uniportal medical thoracoscopy was performed under general with dual channel endotracheal tube in one hundred and eleven patients. Video assisted thoracic surgery was performed in one hundred and eighty seven patients and conversion from medical to VATS procedure was done to thirty nine patients. All patients had stage IV disease with pleura involvement and were under first line pembrolizumab treatment with 200mg (PD-L1 ≥ 50%). Results : The quantitative parameters of the study (expression, PY and cycle) were converted to an ordinal scale to facilitate the performance of statistical analysis. All parameters were examined as dependent against the parameter technique acting as independent to detect potential relationships. The results of multi Y versus X relationship revealed no statistically significant effect (p>0.05) of the three levels of technique against any response considered. Thus we can infer, quite safely, that the innovative operation (level 0) does not differ from the other two conventional methods (levels 2 and 3) through all parameters entered in the model. There was no significant difference between the different pleurodesis techniques. Discussion : Immunotherapy is known to induce in a number of patients pleura effusion and pericarditis. However; pleurodesis is efficient when the appropriate method is performed to every patient. Careful assessment in a case by case manner has to be performed for each patient before any procedure is performed., Competing Interests: Competing Interests: The authors have declared that no competing interest exists., (© The author(s).)
- Published
- 2020
- Full Text
- View/download PDF
50. Pharmacologic and Non-Pharmacologic Interventions for HIV-Neuropathy Pain. A Systematic Review and a Meta-Analysis.
- Author
-
Amaniti A, Sardeli C, Fyntanidou V, Papakonstantinou P, Dalakakis I, Mylonas A, Sapalidis K, Kosmidis C, Katsaounis A, Giannakidis D, Koulouris C, Aidoni Z, Michalopoulos N, Zarogoulidis P, Kesisoglou I, Ioannidis A, Vagionas A, Romanidis K, Oikonomou P, and Grosomanidis V
- Subjects
- Acupuncture Therapy methods, Analgesics therapeutic use, Capsaicin therapeutic use, Humans, Medical Marijuana therapeutic use, Neuralgia virology, Randomized Controlled Trials as Topic, Treatment Outcome, HIV Infections complications, Neuralgia therapy, Pain Management methods
- Abstract
Background and O bjectives : Among HIV infection symptoms, sensory neuropathy (HIV-SN) remains a main cause of suffering, with incidence varying from 13-50%. So far, numerous pharmacological and non-pharmacological treatments have been tested, although few evidence-based analgesic options are available. We conducted an up-to-date systematic review and meta-analysis of the literature in order to evaluate the efficacy and safety of pharmacologic and non-pharmacologic treatments for pain control, in patients with HIV neuropathy. Materials and Methods: We searched MEDLINE, EMBASE, Scopus/Elsevier, The Cochrane Central Register of Controlled Trials (CENTRAL), USA Clinical Trials registry, and The International Web of Science up to April 2019. All randomized controlled trials evaluating efficacy and safety of non-pharmacologic and pharmacologic therapies were included. Efficacy was defined as pain reduction during the study period. Safety was estimated from adverse events. A meta-analysis was performed whenever possible. Results: 27 randomized controlled trials (RCTs) were included for analysis (7 evaluating non pharmacologic interventions, 20 pharmacologic therapies). Non-pharmacologic studies (n = 742) involved seven different therapeutic modalities. Only Acupuncture/Moxibustion showed pain reduction over placebo, Gracely Pain Scale Mean (SD): Acu/Moxa 0.85 (0.12), placebo 1.10 (0.09), p = 0.05. Pharmacologic studies, involving 2516 patients revealed efficacy for capsaicin 8% over placebo (mean difference -8.04 [95% CI: -14.92 -1.15], smoked cannabis (where pooling data for meta-analysis was not possible) and recombinant Nerve Growth Factor. Conclusion: Despite various modalities for pain control in HIV-SN, strongest evidence exists for capsaicin 8% and smoked cannabis, although of low methodological quality. Among non-pharmacologic modalities, only Acu/Moxa gave a marginal beneficial effect in one study, possibly limited by inherent methodological flaws., Competing Interests: The authors declare no conflicts of interest.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.